Robin Joan Steele
Known title: DirectorCIK: 0001301008
Associated companies
Transaction History
| DARE | ▲ Buy | Grant | 26,540 | $0 | 6/30/2026 | View on chart |
| DARE | ▲ Buy | Grant | 26,540 | $0 | 6/30/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
DARE Receives New Patents for HPV and Cervical Treatments
Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.
DARE Receives New Patents for HPV and Cervical Treatments. Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.